GSK is gearing up for the launch of Arexvy, its respiratory syncytial virus (RSV) vaccine for older people, and is counting on efficacy data to persuade US payers of its value in ongoing contract negotiations.
Arexvy is the UK-headquartered company’s most important launch for many years, as it hopes the vaccine can generate around $3bn in annual revenues once it reaches its peak. However, it faces competition from Abrysvo, Pfizer’s also recently approved rival
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?